Source: Contract Pharma

Pharm-Olam: DoD Selects Pharm-Olam to Support to Operation Warp Speed Vax Trials

To support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed.

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
500-1.0K
Robert J. Davie's photo - CEO of Pharm-Olam

CEO

Robert J. Davie

CEO Approval Rating

83/100

Read more